Q2 2026 saw record sales and adjusted EPS above guidance, led by strong pharma demand in injectables and consumer healthcare, while beauty and closures improved sequentially. Emergency medicine headwinds are expected to ease, with gross margins set to recover in H2.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.